Virtus Investment Advisers Inc. Invests $115,000 in Health Catalyst, Inc. (NASDAQ:HCAT)

Virtus Investment Advisers Inc. acquired a new position in Health Catalyst, Inc. (NASDAQ:HCAT) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,297 shares of the company’s stock, valued at approximately $115,000.

Several other institutional investors and hedge funds have also recently modified their holdings of HCAT. Kennedy Capital Management LLC bought a new position in shares of Health Catalyst in the first quarter valued at approximately $8,780,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Health Catalyst by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after acquiring an additional 2,831 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Health Catalyst in the first quarter valued at approximately $98,000. Acadian Asset Management LLC grew its holdings in shares of Health Catalyst by 38.3% in the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after acquiring an additional 200,494 shares in the last quarter. Finally, Gruss & Co. LLC bought a new position in shares of Health Catalyst in the first quarter valued at approximately $188,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Stock Down 1.0 %

Shares of HCAT stock traded down $0.08 on Wednesday, reaching $7.55. The company’s stock had a trading volume of 72,828 shares, compared to its average volume of 586,605. The stock’s 50 day simple moving average is $6.63 and its 200-day simple moving average is $7.48. Health Catalyst, Inc. has a 12-month low of $5.45 and a 12-month high of $14.37. The company has a market capitalization of $445.68 million, a P/E ratio of -4.06 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The business had revenue of $74.72 million for the quarter, compared to the consensus estimate of $74.81 million. Research analysts expect that Health Catalyst, Inc. will post -0.4 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HCAT shares. Wells Fargo & Company reduced their target price on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, May 10th. KeyCorp reaffirmed a “sector weight” rating on shares of Health Catalyst in a report on Wednesday, April 10th. Piper Sandler cut their price target on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating for the company in a report on Thursday, June 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Wednesday, April 10th. Finally, Evercore ISI cut their price target on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.91.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 5,208 shares of Health Catalyst stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total value of $32,029.20. Following the transaction, the chief operating officer now owns 155,215 shares in the company, valued at $954,572.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 8,564 shares of company stock worth $54,889. Company insiders own 2.70% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.